Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165476 · ClinicalTrials.gov registry record · Phase 1
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
A Phase 1 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01165476 is a Phase 1 study that has completed, run by United Therapeutics. The registered enrollment target is 64 participants.
The verdict
NCT01165476, a Phase 1 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the bioavailability of a single 1mg dose of treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent facilities.
Interventions
- DRUG Treprostinil diethanolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165476
The ClinicalTrials.gov registry entry for NCT01165476 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treprostinil diethanolamine is the first listed.
NCT01165476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165476 about?
NCT01165476 is a clinical study titled "Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities". The purpose of this study is to compare the bioavailability of a single 1mg dose of treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent facilities.
What is the current status of trial NCT01165476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2010-07. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01165476?
The interventions under investigation include: Treprostinil diethanolamine (DRUG).
Who is sponsoring clinical trial NCT01165476?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.